Accelerate First in Class R&D with FRONTEO’s unique technologies that systematically discover unreported relationships between diseases and molecules from existing literature information.
FRONTEO, Inc. (Head Office: Tokyo, Japan; Chief Executive Officer: Masahiro Morimoto; hereafter "FRONTEO") is pleased to announce the start of a co-creation project with Eisai Co., Ltd. (Head Office: Tokyo, Japan; hereafter “Eisai”) regarding target discovery in the field of life science AI/AI drug discovery.
This co-creation project combines FRONTEO's Drug Discovery AI Factory (hereafter "DDAIF") *, an AI drug discovery support service specializing in hypothesis generation, with Eisai's accumulated knowledge and technology in pharmaceutical research and development to accelerate research and development of First in Class, groundbreaking drugs.
FRONTEO leverages "KIBIT", an in-house developed specialized AI, and patented natural language processing technologies in the co-creation projects which are currently under discussions with multiple pharmaceutical companies. It is expected to contribute greatly to improving clients’ success rate of drug development and people's health.
The impact of this transaction on the financial results is expected to be minimal.
*AI drug discovery support service that FRONTEO's drug discovery experts, who are well versed in AI and drug discovery, use the natural language processing technology of KIBIT and the unique analysis methods to provide suggestions for target identification, drug repositioning, and the supporting hypotheses.
About unique technology to discover unreported relationships from existing literature information
FRONTEO's AI drug discovery service (DDAIF), which uses the unique technologies of KIBIT, a specialized AI engine developed in-house, discovers unreported relationships from existing literature information, extracts unreported target molecules with high diseases relevance, and presents hypotheses about the underlying disease mechanisms. In recent years, while research on technologies and methodologies for efficiently accessing the information researchers seek from vast amounts of literature has advanced, the reality is that making new discoveries from literature still relies on the researchers' own imagination and coincidence. FRONTEO’s innovative approach in DDAIF makes it possible to find new discoveries in a scientific and systematic manner from non-contiguous sources.
Reference: FRONTEO’s press release on September 9, 2024, Patent application filed for "natural language processing technology that systematically and efficiently discovers unreported relationships from existing literature information", A new technology that overturns common sense in literature searches and revolutionizes science in general, https://www.fronteo.com/pr/20240909
About co-creation project
In conventional AI-based drug discovery, companies conduct dry research (data analysis) and wet research (biological testing) separately. Often, dry research results are advanced to wet research without sufficient exchange of opinions and information between researchers in charge of dry and wet research preventing smooth transition from dry research to wet verification.
This co-creation project will enable close collaboration between FRONTEO and Eisai researchers in dry research, and will achieve a smooth transition to wet research, creating synergistic results that incorporate the knowledge and technologies of both companies.
This co-creation project is also expected to improve the success rate of subsequent drug development in similar cases FRONTEO is currently under discussions with multiple pharmaceutical companies.
About FRONTEO URL: https://www.fronteo.com/
FRONTEO supports experts across various technological fields by providing valuable insights to jumpstart innovation through its proprietary specialized AI engine "KIBIT".
KIBIT implements a unique natural language processing technology (patented in Japan and the United States) that enables high-speed and high-precision analysis of textual repositories without relying on large quantities of training data and computing power, unlike a general-purpose AI engine. By utilizing patented technology that visualizes the structure of relationships between analyzed information, KIBIT provides insights to experts that would otherwise be hidden. In recent years, KIBIT has also been incorporated into analysis tools used for hypothesis generation and target exploration in drug discovery.
In line with FRONTEO’s mission of supporting the information society by providing solutions that discover opportunities and risks that are otherwise hidden in documents, FRONTEO has leveraged KIBIT's unique technology in the fields of Life Science AI, Business Intelligence, Economic Security, and LegalTech AI, Founded in August 2003, listed on Tokyo Stock Exchange Mothers Market (now Tokyo Stock Exchange Growth Market) on June 26, 2007. The offices are located in Japan, the United States, South Korea, and Taiwan. Obtained the first-class marketing license for medical devices, registered controlled medical device sales business. Capital is 898,618,000 yen (as of August 31, 2024).
*FRONTEO, KIBIT and Drug Discovery AI Factory are registered trademarks of FRONTEO in Japan.
Public Relations: pr_contact@fronteo.com
Life Science AI Business Division: https://lifescience.fronteousa.com/contact/